Literature DB >> 15757907

Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.

Kaleeckal G Harikumar1, Laurence J Miller.   

Abstract

Changes in receptor conformation are believed to be key for ligand-induced regulation of cellular signaling cascades. However, little information exists about specific conformations of a receptor. We recently applied fluorescence resonance energy transfer to determine distances from distinct points distributed over the surface and within the helical bundle of the cholecystokinin receptor to the amino terminus of a full agonist CCK analogue (Harikumar, K. G., Pinon, D. I., Wessels, W. S., Dawson, E. S., Lybrand, T. P., Prendergast, F. G., and Miller, L. J. (2004) Mol. Pharmacol. 65, 28-35). Here, we apply the same experimental strategy to determine distances from the same receptor positions to an analogous point at the amino terminus of structurally related partial agonist (Alexa488-Gly-[(Nle(28,31))CCK-26-32]phenethyl ester) and antagonist (Alexa488-Gly-[(D-Trp31, Nle(28,31))CCK-26-32]phenethyl ester) ligands. A high degree of spectral overlap and fluorescence transfer was observed for ligand-occupied fluorescent-tagged receptors with no transfer observed for the ligand-occupied pseudo-wild type null cysteine-reactive mutant receptor (C94S). For the partial agonist, calculated distances to receptor positions 94, 102, 204, and 341, representing sites within the helical confluence, and the first, second, and third loops, were 21 +/- 0.4, 18 +/- 0.4, 25 +/- 1, and 17 +/- 1 angstroms, not different from those measured previously for the analogous full agonist. For the antagonist, the analogous distances were 21 +/- 2, 28 +/- 2, 15 +/- 1 and 21 +/- 1 angstroms. Distances to the first and third loops were longer and the distance to the second loop was shorter for the antagonist relative to both the full and partial agonist probes, whereas all three probes demonstrated similar distances to the intrahelical reference point. This supports the possibilities of changes in the conformation of the probe and/or the receptor induced by structurally similar ligands having distinct intrinsic biological activities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15757907     DOI: 10.1074/jbc.M410834200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements.

Authors:  Agnes Szabó; Gábor Horváth; János Szöllosi; Peter Nagy
Journal:  Biophys J       Date:  2008-05-16       Impact factor: 4.033

2.  Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Erin E Cawston; Laurence J Miller
Journal:  Assay Drug Dev Technol       Date:  2011-03-11       Impact factor: 1.738

Review 3.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

4.  Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Fan Gao; Delia I Pinon; Laurence J Miller
Journal:  Biochemistry       Date:  2008-08-13       Impact factor: 3.162

5.  Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor.

Authors:  Fan Gao; Patrick M Sexton; Arthur Christopoulos; Laurence J Miller
Journal:  Bioorg Med Chem Lett       Date:  2008-06-20       Impact factor: 2.823

Review 6.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

7.  Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.

Authors:  Piotr F J Lipiński; Piotr Garnuszek; Michał Maurin; Raphael Stoll; Nils Metzler-Nolte; Artur Wodyński; Jan Cz Dobrowolski; Marta K Dudek; Monika Orzełowska; Renata Mikołajczak
Journal:  EJNMMI Res       Date:  2018-04-16       Impact factor: 3.138

8.  Sensitivity of cholecystokinin receptors to membrane cholesterol content.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-18       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.